CL2022002405A1 - Inhibidores de la replicación del virus de inmunodeficiencia humana - Google Patents

Inhibidores de la replicación del virus de inmunodeficiencia humana

Info

Publication number
CL2022002405A1
CL2022002405A1 CL2022002405A CL2022002405A CL2022002405A1 CL 2022002405 A1 CL2022002405 A1 CL 2022002405A1 CL 2022002405 A CL2022002405 A CL 2022002405A CL 2022002405 A CL2022002405 A CL 2022002405A CL 2022002405 A1 CL2022002405 A1 CL 2022002405A1
Authority
CL
Chile
Prior art keywords
immunodeficiency virus
human immunodeficiency
virus replication
replication inhibitors
inhibitors
Prior art date
Application number
CL2022002405A
Other languages
English (en)
Inventor
P Gillis Eric
IWUAGWU Christiana
Original Assignee
Viiv Healthcare Uk No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Uk No 5 Ltd filed Critical Viiv Healthcare Uk No 5 Ltd
Publication of CL2022002405A1 publication Critical patent/CL2022002405A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se establecen los compuestos de la Fórmula I, que incluyen sales farmacéuticamente aceptables de los mismos, y composiciones y métodos para tratar la infección por el virus de inmunodeficiencia humana (VIH):
CL2022002405A 2020-03-06 2022-09-05 Inhibidores de la replicación del virus de inmunodeficiencia humana CL2022002405A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062985937P 2020-03-06 2020-03-06
US202063040051P 2020-06-17 2020-06-17

Publications (1)

Publication Number Publication Date
CL2022002405A1 true CL2022002405A1 (es) 2023-04-14

Family

ID=74859494

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022002405A CL2022002405A1 (es) 2020-03-06 2022-09-05 Inhibidores de la replicación del virus de inmunodeficiencia humana

Country Status (12)

Country Link
US (1) US20230355626A1 (es)
EP (1) EP4114834A1 (es)
JP (1) JP2023517043A (es)
KR (1) KR20220151655A (es)
CN (1) CN115551858A (es)
AU (2) AU2021231447A1 (es)
BR (1) BR112022017832A2 (es)
CA (1) CA3170536A1 (es)
CL (1) CL2022002405A1 (es)
IL (1) IL296182A (es)
MX (1) MX2022011016A (es)
WO (1) WO2021176366A1 (es)

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
US9540343B2 (en) 2011-07-06 2017-01-10 Gilead Sciences, Inc. Compounds for the treatment of HIV
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
JP5860197B1 (ja) 2013-01-09 2016-02-16 ギリアード サイエンシーズ， インコーポレイテッド ウイルス感染症を処置するための治療用化合物
NZ631762A (en) 2013-01-09 2017-02-24 Gilead Sciences Inc 5-membered heteroaryls and their use as antiviral agents
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
TWI706945B (zh) * 2013-03-01 2020-10-11 美商基利科學股份有限公司 供治療反轉錄病毒科病毒感染之治療性化合物
JP6466433B2 (ja) 2013-10-24 2019-02-06 ビーブ・ヘルスケア・ユーケイ・（ナンバー５）・リミテッドＶｉｉＶ Ｈｅａｌｔｈｃａｒｅ ＵＫ （Ｎｏ．５） Ｌｉｍｉｔｅｄ ヒト免疫不全ウイルス複製の阻害剤
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
PT3186239T (pt) 2014-08-29 2019-01-10 Gilead Sciences Inc Agentes antirretrovirais
US9855230B2 (en) 2014-09-09 2018-01-02 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
CA2983201A1 (en) 2015-04-23 2016-10-27 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
KR20180005673A (ko) 2015-04-23 2018-01-16 비브 헬스케어 유케이 (넘버5) 리미티드 인간 면역결핍 바이러스 복제 억제제
CA3021227C (en) 2016-08-19 2020-11-03 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
TW201906834A (zh) 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
TW202024061A (zh) 2017-08-17 2020-07-01 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
KR102587510B1 (ko) 2018-02-15 2023-10-11 길리애드 사이언시즈, 인코포레이티드 피리딘 유도체 및 hiv 감염을 치료하기 위한 그의 용도
CA3090280A1 (en) 2018-02-16 2019-08-22 Gilead Sciences, Inc. Methods and intermediates for preparing therapeutic compounds useful in the treatment of retroviridae viral infection
WO2019198024A1 (en) 2018-04-11 2019-10-17 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
US11919897B2 (en) * 2018-09-20 2024-03-05 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
EP3873607B1 (en) * 2018-10-29 2023-11-29 VIIV Healthcare UK (No.5) Limited Quinazolinyl-indazole derivatives and their use as inhibitors of human immunodeficiency virus replication
EP3876942A1 (en) * 2018-11-05 2021-09-15 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
WO2020095177A1 (en) * 2018-11-05 2020-05-14 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
UY38559A (es) * 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
PE20220510A1 (es) * 2019-06-19 2022-04-07 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicacion del virus de inmunodeficiencia humana

Also Published As

Publication number Publication date
WO2021176366A1 (en) 2021-09-10
JP2023517043A (ja) 2023-04-21
EP4114834A1 (en) 2023-01-11
AU2024201719A1 (en) 2024-04-04
AU2021231447A1 (en) 2022-09-22
BR112022017832A2 (pt) 2022-11-01
IL296182A (en) 2022-11-01
CN115551858A (zh) 2022-12-30
CA3170536A1 (en) 2021-09-10
KR20220151655A (ko) 2022-11-15
MX2022011016A (es) 2022-11-30
US20230355626A1 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
CO2021004679A2 (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
UY37710A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
UY36648A (es) Inhibidores de la replicación del virus de inmunodeficiencia humana
DOP2023000023A (es) Agonistas del glp-1 heterocíclicos
UY36649A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
UY38559A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
CO2021017504A2 (es) Derivados de benzisoxazol sulfonamida
AR119174A1 (es) Inhibidores de la replicación del virus de inmunodeficiencia humana
ECSP19041050A (es) Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih
CL2021000329A1 (es) Compuestos útiles en terapia del vih
ECSP22038509A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
CR20180091A (es) 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del vih
CL2021002309A1 (es) Compuestos útiles en la terapia del vih
CL2022002386A1 (es) Compuestos de amino pirimidina fusionados
ECSP22049160A (es) Derivados de bencimidazol
CO2022011947A2 (es) Compuestos tetracíclicos para el tratamiento de infecciones por vih
UY37555A (es) Derivados de ácido piridin-3-il-acético como inhibidores de la replicación del virus de la inmunodeficiencia humana
CO2023017151A2 (es) Inhibidores de ripk1 de nicotinamida
CL2021000184A1 (es) Piridopirimidinas como inhibidores del receptor de histamina h4
CL2022002405A1 (es) Inhibidores de la replicación del virus de inmunodeficiencia humana
CO2023012702A2 (es) Derivados de diazepina útiles en el tratamiento de clostridium difficile
AR124868A1 (es) Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih
CL2022002817A1 (es) Inhibidores de replicación del virus de inmunodeficiencia humana
CU20220045A7 (es) Compuestos derivados sustituidos de pirimidina para el tratamiento y prevención de la infección por vih
BR112021025877A2 (pt) Derivados de amina terciária e seus usos para tratar uma infecção viral